Vimarsana
Biggest News Aggregation in the World

Page 18 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Bio Today - Breaking & Trending Today

Erytech Pharma S.A.: ERYTECH to Participate in the Upcoming April Investor Conferences - Vimarsana News

Erytech Pharma S.A.: ERYTECH to Participate in the Upcoming April Investor Conferences

ERYTECH to Participate in the Upcoming April Investor Conferences Cambridge, MA (U.S.) and Lyon (France), March 28, 2022 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), a

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 - Vimarsana News

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 - Vimarsana News

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

11.03.2022 - ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 Conference call and webcast on Tuesday, March 14, 2022at 8:30am EDT / 1:30pm CET         Progress towards seeking approval of GRASPA for the treatment of ALL ...

Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease - Vimarsana News

Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Press ReleaseNicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseMarch 2nd, 2022 - release at 7:30 am CET Sophia

Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China - Vimarsana News

Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China

Press ReleaseNicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China ZERVIATE (cetirizine ophthalmic solution), 0.24% was non-inferior to comparator